Additionally, we demonstrated that select FNDs significantly increased apoptosis in CRC metastatic and cancer stem cells. Therefore, FNDs hold considerable promise in the treatment of metastatic CRC, through elimination of both regular cancer cells and cancer stem cells.
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States (1) . This high mortality rate is largely attributed to tumor metastasis and recurrence (2) . At initial presentation, more than half of all patients display metastatic disease in regional lymph nodes or systemic organs (e.g., liver). The five-year survival rate for patients with metastatic CRC is approximately 13%, as compared to 90% for non-metastatic disease (1) . A growing body of evidence suggests that cancer stem cells play a role in the resistance and spread of cancer cells (2) (3) (4) . Cancer stem cells are a subpopulation of tumor cells that are capable of self-renewal and display resistance to DNA damage-induced cell death, a ruinous property that allows metastatic tumors to survive initial treatments and re-populate. Developing new anti-neoplastic agents that selectively target cancer stem cells represents a potentially valuable treatment to improve CRC outcomes (2) (3) (4) .
Cancer stem cells possess demanding metabolic requirements and survival mechanisms that are potential targets for treatment (5) . One such critical pathway involves AMP-activated protein kinase (AMPK), which coordinates growth, autophagy, and metabolism (6) . AMPK acts as a metabolic sensor for the ratio of AMP to ATP in cells and has several downstream transcriptional targets (6) . Among the anti-neoplastic effects of AMPK activation are cell cycle arrest through stabilization of p53 and cyclin-dependent kinase inhibitors p21 waf1 and p27 kip1 , inhibition of macromolecular synthesis, inhibition of mTORC1, and inhibition of the Warburg effect (7, 8) . In support of the particular importance of AMPK in cancer cells and cancer stem cells, the widely studied AMPK activator, metformin, reduces cancer incidence in diabetic populations for many different cancers, including CRC (9) . Furthermore, in vitro and in vivo studies with metformin specifically show cytotoxicity toward cancer stem cells (10, 11) . We identified the anti-neoplastic effects of fluorinated N,N'-diarylureas (FNDs) in a high-throughput screening program (12) and found that several potent FNDs inhibited growth of CRC cell lines through inhibition of the mTOR pathway (12) . Overexpression of mTORC1 and mTORC2 components, Raptor and Rictor, is important to tumorigenesis (13) , and the activation of AMPK regulates cell growth by suppressing mTORC1 through direct phosphorylation of the tumor suppressor, TSC2, and Raptor (6) . Through this mechanism, we anticipated that AMPK activation would directly inhibit CRC cell proliferation.
In this study, we investigated the ability of eight FNDs to inhibit growth and induce apoptosis in CRC metastatic cell lines and stem cells. Activation of AMPK by all FND compounds successfully inhibited cell cycle progression and subsequent cellular proliferation.
These results demonstrate that FNDs exhibit considerable promise in the treatment of metastatic CRC, predominantly through the inhibition of CRC stem cells.
MATERIALS AND METHODS

FNDs.
FNDs were synthesized as previously described (12) . Table 1 shows the FNDs used in this study. Stock solutions (10 mM) in dimethyl sulfoxide (DMSO) were stored at -20°C. Cancer Center, Houston, TX); STR validation analysis (Bio-Synthesis, Lewisville, TX) yielded a full DNA profile and no contamination by another human cell line was detected; there were no matches after searching ATCC, JCRB or DSMZ databases. HCT116 pik3ca wild-type and mutant cell lines were a gift from Dr. J. Wang (14) . Human CRC stem cell line 1 (#36112-39; lot 6 #12121800-05) and stem cell line 2 (#36112-39; lot #1313161-12) were purchased from Celprogen (Torrance, CA). Cancer stem cells were limited to less than 12 passages.
Cell lines were routinely grown as monolayer cell cultures in 5% CO 2 in air, and 100% relative humidity at 37°C. HT29 and KM20 cell lines were grown in McCoy's 5A medium 
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cells. We performed a high-throughput screen of N,N'-diarylureas to identify potent AMPK activators and selected eight active agents (Table 1)(12). Next, HT29 cells were treated with the 8 agents (FND 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h) for 48h. Decreased cell viability was evident at a drug dose as low as 5 µM, and was below 50% for all 8 compounds treated at the 25 µM dose ( Table 2) . To determine whether the prominent decrease in cell viability was due to cell cycle inhibition or apoptosis induction, KM20 and HT29 CRC cells were treated with each of the 8
FNDs for 24h at 25 μM or 50 μM. Cyclin D1 expression and PARP cleavage were analyzed by western blot. Cyclin D1 expression was drastically decreased in both cell lines after treatment with FND 4b, 4c, 4d, 4e, 4f, 4g, and 4h at 25 µM (Fig. 1A) . Prominent PARP cleavage was observed after treatment at the 50 µM dose, notably after treatment with the 4b compound ( and 50 µM of FND 4b. Our results showed a dose-dependent AMPK activation after FND 4b treatment (Fig. 2B) .
Next, we used compound 4b to evaluate dose-dependent AMPK activation in KM20 and HT29 cells. We observed AMPK activation starting with as little as 10 µM (Fig. 3A) . We also examined the dose dependent effects of FND 4b treatment on cell viability (Fig. 3B) , cell cycle, and apoptosis induction in KM20 and HT29 cells. KM20 cells were more sensitive to compound 4b treatment and showed marked suppression of cyclin D1 expression at a dose of 10 µM. PARP cleavage was detected in both cell lines starting at a 40 µM dose. (Fig. 4A) . These results show that the HCT116 pik3ca mutant and wild-type cells have a similar pattern of cell cycle inhibition and apoptosis in response to FND 4b treatment.
Metformin, which is a known activator of AMPK and is used for diabetes treatment and cancer prevention, activates AMPK at millimolar levels (15) . AMPK downregulates TOR/S6K (Fig. 5A) . Low-dose FND 4b treatment resulted in a strong AMPKα activation, and decreased cyclin D1 expression in CRC stem cells at 48h (Fig. 5B, C) . Next, we established a cell line from a patient-derived xenograft (PDX) and treated it with low-dose FND 4b for 48h. Cyclin D1 expression was markedly suppressed in the PDX cell line (Fig. 5D) . FND treatment at 5, 7.5 and 10 µM significantly decreased stem cells and PDXL proliferation (Fig. 5 B, C, D; lower panels) . Low-dose FND treatment did not increase PARP cleavage in all tested cells (data not shown). These results demonstrate a longlasting effect of low-dose FND 4b treatment on AMPKα activation and cell cycle inhibition.
DISCUSSION
The central regulatory role played by AMPK in energy homeostasis makes it an attractive target for treatment of various diseases such as diabetes and cancer (6, 7, 17) . Recent efforts have focused on elucidating the complex role of AMPK in cancer cell viability (18) . We examined the lines to evaluate their potential utility as chemotherapeutic agents for CRC. The FNDs that were used in this study represent a new class of AMPK activators with no effect on AKT or ERK, unlike other N,N' diarylureas [12] . We confirmed that FND treatment of CRC metastatic and stem cell lines resulted in dose-dependent AMPK activation. High doses of traditional AMPK activators, such as AICAR and metformin, were required to achieve anti-cancer effects (10) (11) (12) 19 ). However, similar to FNDs, more recent AMPK activators showed anti-tumorigenic effects at lower concentrations. Chen et al. (19) showed that plumbagin, an AMPK activator, induced apoptosis and inhibited growth of CRC cell lines at a treatment concentration of 10 µM. Kaushik et al. (20) showed that honokiol, another AMPK activating compound, inhibited melanoma growth and spheroid-forming capacity (i.e., stemness) through AMPK activation at concentrations up to 50 µM. Finally, Valtorta et al. (21) showed that 1-4 diaryl-azetidinone, also a novel AMPK activator, inhibited human CRC xenografts in mouse models at IC 50 in the nM to 1 µM range. Taken together, these studies suggested that targeting cancer cells with novel AMPK activators represent an effective strategy for the treatment of different types of cancers.
Thus, the beneficial effects on metastatic cancer cells by AMPK activation provide a rationale for further studies, to determine the potential clinical utility of AMPK activators, like FNDs, on cancer stem cells.
In our study, we evaluated the effect of FNDs on CRC stem cells. Many cancer stem cell models have been described, but a unifying theme in tumorigenesis is that tumors are not homogeneous. A hierarchical structure within tumors includes a small subset of cells with longterm self-renewal and differentiation capacity (3) . CRC, in particular, is known to possess cancer stem cells (22) . In order to survive, re-populate, and differentiate, cancer stem cells have While the specific role of AMPK in cancer stem cells compared with the non-stem cell population has not yet been fully characterized, several studies have shown that metformin, an AMPK activator, is preferentially cytotoxic to cancer stem cells in pancreatic and breast cancers (10, 11, 23) . Similarly, in our present study, we showed that FND treatment resulted in cell cycle arrest in CRC stem cells. AMPK activation led to inhibition of macromolecular synthesis, inhibition of mTORC1, and onset of the 'anti-Warburg effect' (7, 24, 25) , all of which led to the inhibition of cancer cell proliferation. Hardie and Alessi (7) described several AMPK tumor suppressor functions that included cell cycle arrest through stabilization of p53, p21 and p27. 
Particularly in cancer stem cells, it is likely that the anti-Warburg effect targets the utilization of anaerobic glycolysis by cancer stem cells, and decreases their ability to use AKT-mTOR. AMPK activation of apoptosis resulted from p53 phosphorylation; phosphorylated AMPK subsequently accumulated in the mitochondria and interacted with Bak to induce apoptosis (8) . Our results demonstrated that AMPK activation reduced the ability of cancer stem cells to hijack energy metabolism for growth and proliferation and triggered an apoptotic cascade. In summary, we demonstrated that FNDs activated AMPK at micromolar concentrations, which resulted in consistent cell cycle arrest and apoptosis in all cancer cell lines that were studied. These findings provide additional information regarding the role of AMPK activation in cancer stem cells and demonstrate a potential role of FNDs in the treatment of metastatic CRC. Table 1 . Fluorinated N,N'-diarylureas (FNDs) with substituents X or Y in the "first" aryl ring and substituents A,B,C,D in the "second aryl" ring. AMPK activation ratios were relative to compound 3 from a previous study [13] . was assessed by western blot analysis; β-actin was used as a loading control. 
